«This approval will open the floodgates for these kinds of therapy to be used in many
different leukemias, lymphomas, solid
tumors, myelomas,» Dr. Prakash Satwani, a
pediatric hematologist - oncologist at Columbia University Medical Center, told Business Insider.
Researchers leading the largest genomic
tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and
pediatric patients with many
different types of cancer, and that some patients can benefit by receiving precision drugs targeted to their
tumors» mutations or being enrolled in clinical trials.